Cite
HARVARD Citation
Wu, F. et al. (n.d.). 1505TiPA phase III, randomized, open-label, multicenter study of SHR-1210 (anti-PD-1 antibody) in combination with pemetrexed and carboplatin as first line therapy in subjects with advanced/metastatic non-squamous non-small cell lung cancer. Annals of oncology. p. . [Online].